Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-Guided Neoadjuvant Therapy in HER2-Positive Breast Cancer
NCT07528716Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in breast cancer, sponsored by Fudan University. Started May 2026; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07528716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528716.